Vanta BioscienceBOM:540729 57 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 57/100 and a GF Value™ of ₹12.03 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Vanta Bioscience ranks worse than 95.7% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Vanta Bioscience's
Operating Income
for the
six
months ended in Mar. 2026 was ₹16.15 Mil. Vanta Bioscience's Interest Expense for the
six
months ended in Mar. 2026 was ₹1.05 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Vanta Bioscience Ltds earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
The historical rank and industry rank for Vanta Bioscience's Interest Coverage or its related term are showing as below:
BOM:540729'
s Interest Coverage Range Over the Past 10 Years
Min: 0.81 Med: 1.5 Max: 3.3
Current: 0.81
BOM:540729's Interest Coverage is ranked worse than 95.7% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs BOM:540729: 0.81
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Vanta Bioscience Interest Coverage Related Terms
Vanta Bioscience Interest Coverage Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:540729 vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Vanta Bioscience (BOM:540729) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vanta Bioscience and its competitors. Over the past decade, Vanta Bioscience's Interest Coverage has ranged from 0.81 to 3.30. According to the industry distribution chart, Vanta Bioscience ranks #89 out of 93 companies in the Medical Diagnostics & Research industry, placing it in the top 95.7%.
Is Vanta Bioscience's Interest Coverage too high?
Vanta Bioscience's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 3.30. Based on the distribution chart, Vanta Bioscience ranks #89 out of 93 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vanta Bioscience has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #89 out of 93 companies for Interest Coverage. This places Vanta Bioscience in the lower half of its industry. The industry median Interest Coverage is 9.05. Historically, Vanta Bioscience's own Interest Coverage has ranged from 0.81 to 3.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.03, compared to a current price of ₹25.29 — trading 110.2% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Vanta Bioscience's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 110.2% above its estimated GF Value™ of ₹12.03.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Interest Coverage: 0 (At Loss)
GF Value™: ₹12.03 vs. price of ₹25.29 (110.2% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
57GF Score
Get the complete analysis for BOM:540729
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
